Federal Register #FDA-2026-N-7605

FDA Request for Information: Quantitative Medicine Innovation Network (QMIN) Stakeholder Input

The Food and Drug Administration (FDA), under the Department of Health and Human Services, is seeking stakeholder input to inform the creation of a Quantitative Medicine Innovation Network (QMIN). - Government Buyer: - Department of Health and Human Services (HHS) - Food and Drug Administration (FDA) - Center for Drug Evaluation and Research (CDER) - Purpose: - Request for Information (RFI) to gather feedback from industry, academia, healthcare providers, patient groups, and other stakeholders - Focus on shaping the structure, priorities, and activities of the proposed QMIN - Products/Services Requested: - No specific products, part numbers, or quantities are being procured - No OEMs or vendors are named - The RFI seeks input on community needs, engagement mechanisms, collaborative projects, and innovative approaches in quantitative medicine - Unique/Notable Requirements: - Emphasis on stakeholder engagement and research collaboration - Input will guide the development of a network to accelerate quantitative medicine in drug development and regulatory science - No direct procurement or acquisition of goods/services at this stage

Description

The Food and Drug Administration (FDA) is requesting information to develop a Quantitative Medicine Innovation Network (QMIN). The goal of QMIN is to create a collaborative platform that accelerates the application of quantitative medicine approaches to improve drug development, regulatory science, and clinical decision-making. The FDA seeks feedback from industry, academia, healthcare providers, patient groups, and other stakeholders on community needs, engagement mechanisms, collaborative projects, and innovative approaches related to quantitative medicine. Information submitted will help shape the structure, priorities, and activities of the QMIN.

View original listing